Bruce Jackson

Jonathan Aschoff

- Biofrontera Inc. (BFRI) specializes in photodynamic therapy for **actinic keratosis (AKs)**, with its FDA-approved Ameluz product having patent protection until **2043**.  **[1858685_2162684_1]** 
- The company reported **$37.3 million** in revenue for 2024 and **$17.6 million** for Q2 year-to-date 2025, showing continued growth.  **[1858685_2162684_1]** **[1858685_2162684_3]** 
- Biofrontera is transitioning to a vertically integrated U.S. pharmaceutical company by acquiring all IP and NDA rights for Ameluz in **Q2 2025**, which is expected to increase gross margins from the high 40s/low 50s to **80-85%**.  **[1858685_2162684_1]** 
- Significant label expansion is underway, with PDUFA dates expected for basal cell carcinoma in **Fall 2026** and for trunk and extremities in **mid-2027**, alongside ongoing trials for acne.  **[1858685_2162684_3]** **[1858685_2162684_5]** 
- The company anticipates reaching **break-even in 2026** based on current growth and financial projections.  **[1858685_2162684_5]**

Biofrontera (BFRI)